Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Xinqiao Hospital of Chongqing
Institut Curie
University Health Network, Toronto
Fate Therapeutics
Washington University School of Medicine
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
TCR2 Therapeutics
TCR2 Therapeutics
CStone Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National University Hospital, Singapore
TCRCure Biopharma Ltd.
University of Pittsburgh
Zhejiang University
Centre Hospitalier Universitaire Vaudois
Shanghai NK Cell Technology Co., LTD
Chinese PLA General Hospital
Fudan University
St. Jude Children's Research Hospital
China Medical University, China
Letolab
Centre Hospitalier Universitaire Vaudois
Chinese PLA General Hospital
Gilead Sciences
Chinese PLA General Hospital
Shanghai Pudong Hospital
Fujian Cancer Hospital
The First People's Hospital of Lianyungang
Fred Hutchinson Cancer Center
MaxCyte, Inc.
Centre Hospitalier Universitaire Vaudois
Aduro Biotech, Inc.
University of California, San Francisco
Genexine, Inc.
Emory University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Fred Hutchinson Cancer Center
NYU Langone Health
Miller Children's & Women's Hospital Long Beach
National Cancer Institute (NCI)